Annual General Meeting of April 30, 2021
30 April 2021 - 5:56PM
Annual General Meeting of April
30, 2021
- Approval of the financial statements for the fiscal year
2020
- Dividend of €3.20 per share payable as of May 7, 2021
- Board composition: renewals, ratification of a co-opting
Director and appointment of one new Director
Paris, France – April
30, 2021
– The Combined General Shareholders’ Meeting of
Sanofi was held on April 30, 2021, without the physical presence of
its shareholders, in accordance with the derogating measures
adapting the rules governing the deliberation of general meetings
taken by the French authorities as part of the fight against
COVID-19, at the Company’s registered office in Paris, under the
chairmanship of Serge Weinberg. All resolutions submitted to the
vote were adopted by the shareholders.
The General Meeting approved the individual
Company and consolidated financial statements for the fiscal year
2020. The General Meeting decided on the distribution of a cash
dividend to the amount of €3.20 per share with payment as of May 7,
2021.
The General Meeting also renewed Fabienne
Lecorvaisier and Melanie Lee as Directors, ratified the co-opting
of Gilles Schnepp and approved the appointment of Barbara Lavernos
in replacement of Laurent Attal.
On the proposal of the Nomination, Governance
and CSR Committee, Rachel Duan was appointed member of the
Remuneration Committee, Lise Kingo member of the Nomination,
Governance and CSR Committee and Gilles Schnepp member of the
Strategic Review Committee.
Furthermore, the Board of Directors took note of
the appointment of Wolfgang Laux and Yann Tran to replace Marion
Palme and Christian Senectaire respectively as Directors
representing employees.
Following the General Meeting, the Board of
Directors is comprised of 15 members, of whom seven are women and
two are Directors representing employees. The Board of Directors
remains for a large majority comprised of Independent
Directors.
The voting results and the videocast of the Annual General
Meeting are available on:
www.sanofi.com/AG2021
About Sanofi Sanofi is dedicated to
supporting people through their health challenges. We are a global
biopharmaceutical company focused on human health. We prevent
illness with vaccines, provide innovative treatments to fight pain
and ease suffering. We stand by the few who suffer from rare
diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is
transforming scientific innovation into healthcare solutions around
the globe. Sanofi, Empowering Life |
Media Relations ContactSandrine GuendoulTel.: +33
(0)6 25 09 14 25sandrine.guendoul@sanofi.com |
Investor
Relations ContactArnaud DelépineTel.: +33 (0)1 53 77 45
45investor.relations@sanofi.com |
|
Sanofi is dedicated to supporting people through
their health challenges. We are a global biopharmaceutical company
focused on human health. We prevent illness with vaccines, provide
innovative treatments to fight pain and ease suffering. We stand by
the few who suffer from rare
Sanofi (EU:SAN)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Sanofi (EU:SAN)
Historical Stock Chart
Von Apr 2023 bis Apr 2024